Skip to main content

People in the News: Paul Grint, Bruce Huebner, Thomas McLain

Premium

Illumina said in a recent filing with the US Securities and Exchange Commission that Paul Grint plans to retire from the firm's board of directors, effective as of the next Illumina stockholder meeting.

Grint has been a director since 2005. He's currently senior vice president at Forest Research Institute, and was previously the chief medical officer at Kalypsys. He has also served as an executive at Zephyr Sciences, Pfizer, IDEC Pharmaceuticals, and Schering-Plough.


Vermillion has appointed Bruce Huebner to be company chairman. Huebner had been serving as Vermillion's interim CEO and president until earlier this month when the company earlier named Thomas McLain to those positions.

Prior to joining Vermillion, Huebner held various managerial posts in the life sciences and healthcare industries. From 2005 to 2008, he served as president of Osmetech Molecular Diagnostics, now GenMark Diagnostics. And from 2002 and 2004, he was president and chief operating officer of Nanogen.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.